Sebia brings to market new Capillarys 3 Tera automated system with CE mark HbA1c and serum protein testing, and immunotyping

Flexible, modular and scalable; Capillarys 3 Tera is the first in Sebia's new range of automated electrophoresis solutions

This new range will be showcased at the IFCC EuroMedLab congress in Paris, France, from June 21 to 25 (Booth F042)

Paris, France, June 10, 2015 – Sebia, the world leader in capillary electrophoresis, today announces that Capillarys 3 Tera now has the CE mark for HbA1c and serum protein testing, and immunotyping. The CE mark for these tests is the first step in bringing the Capillarys 3 suite to market.

In connection with its recent entry into the market for HbA1c, Sebia has designed Capillarys 3, a flexible, modular and scalable range of automated electrophoresis solutions to meet the needs of medical laboratories in terms of flexibility, productivity, safety, reliability and separation quality. This range will help laboratories to meet new challenges in the sector, such as laboratory consolidation, the creation of new, high-throughput technical platforms and increased productivity. The first laboratories to use the solution are now installing it.

Capillarys 3 Tera is the first instrument in the range. It will be made available in a number of configurations to provide any laboratory with a truly modular solution featuring:

- A high capacity tube loader (up to 500 tubes), considerably increasing system autonomy
- A standalone configuration with up to three interconnected instruments. The Capillarys 3 Tera MC (Maximum Capacity) analysis work-cell will provide full working autonomy for use either in dedicated mode, for high volume throughput using a single technique, or in multi-parameter mode
- Connection to an automated external analytical chain in the form of Capillarys 3 Tera TLA (Total Laboratory Automation)

The instruments in the Capillarys 3 suite are based on Sebia's proven capillary technology. They provide results that are entirely consistent with those achieved with other Sebia capillary electrophoresis instruments (the Capillarys/Minicap ranges). It has an equivalent analytical performance, helping to guarantee continuity in tracking patient data between laboratories. Fitted with 12 capillaries and next-generation robotics, Capillarys 3 Tera can be used to analyze samples at a higher throughput than its predecessors.

"We are delighted to have begun marketing Capillarys 3," said Benoit Adelus, Sebia's chairman and CEO. "The CE mark means that we can now offer our high value-added analytical solution to health care professionals in a large number of countries."

The Capillarys 3 suite incorporates the latest advances in technology. It offers high throughput depending on configuration (from 130 to 390 tests per hour for proteins and from 70 to 210 tests per hour for HbA1c), substantial sample and reagent capability, full RFID-based next-generation traceability, cap-piercing technology for working directly with capped primary tubes and considerable flexibility for effective workflow organization. In due course it will be possible to analyze a wide variety of sample types: serum, urine, whole blood, capillary blood and Guthrie cards. The Capillarys 3 suite delivers a separation technique that does not compromise on throughput or resolution.

Capillarys 3 Tera uses the Phoresis Core software, which has three major features:

- Unlimited data storage with retrieval of patient results history
- Network connection to all other Sebia systems or to remote laboratories
- A decentralized validation platform

Sebia will phase in to market other instruments in the suite, starting with the tube loader and followed by Capillarys 3 Tera MC, then Capillarys 3 Tera TLA. The full range will be previewed at the IFCC EuroMedLab congress in Paris, France, June 21 to 25, 2015. The company will also introduce testing for other components, such as HbA1c in capillary tubes, hemoglobinopathy screening, CDT quantification, urinary protein electrophoresis and immunotyping, along with additional tests that are currently under development.
Find out more about Capillarys 3 Tera:
http://www.sebia.com/en-EN/produits/capillarys-3-tera

About Sebia
Sebia develops, manufactures and commercializes protein electrophoresis tests and analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, diabetes and hemoglobin disorders. Sebia's focus on electrophoresis techniques allows a sustained R&D program, providing access to genuine innovations to any lab. Both agarose gel and capillary assays and their dedicated automation are designed to be integrated into the same routine workflow; for gel (Assist, Hydrasys 2 Scan) and for capillary electrophoresis (Capillays 2, Minicap).
In 2011 Sebia introduced Capillarys 2 Flex Piercing, the most advanced capillary technology, providing a high level of performance and walk-away automation. Tests include serum proteins, urine proteins, immunotyping, CDT measurement and hemoglobinopathy screening for whole blood in primary capped tubes.

Recently Sebia has diversified its activity in the field of diabetes to fulfill the growing worldwide demand for more accurate and reproducible methods of HbA1c measurement. Sebia now offers a clear-cut and precise HbA1c test on Capillarys 2 Flex Piercing and Minicap Flex Piercing. In 2015, the company launched the high-speed automation electrophoresis program, Capillarys 3.

More information: http://www.sebia.com/

Media Contacts & Analysts
Andrew Lloyd & Associates
Juliette dos Santos / Sandra Régnavaque
juliette@ala.com / sandra@ala.com
Tel: +33 1 56 54 07 00
